We have used this antibody for IHC staining of 4% PFA perfused mouse brain tissue (vibratome sections). The first batch of the antibody worked okay, but the second and third batch didn’t give good results.
This antibody was included in a study testing 49 commercial available Tau antibodies including both pan-Tau antibodies and antibodies specifically recognizing Tau with post-translational modifications (PTM).
The antibodies were tested by peptide array to assess PTM specificity and by immuno-blotting of mouse brain lysates obtained from hTg-Tau (expressing all six human isoforms of Tau) and Tau knock out mice to test Tau specificity. A subset of 35 antibodies was subsequently tested by immunofluorescence staining of human iPSC derived neurons (see reference below for further details)
WB: 1/1000, Very good – strong signal for tau, no non-specific signal
The study was published in Ercan et al. Molecular Neurodegeneration (2017) 12:87 “A validated antibody panel for the characterization of tau post-translational modifications” and demonstrates that commercially available antibodies show a significant lack of specificity. In particular, PTM-specific antibodies very often recognize non-modified version of Tau.
On December 27, 2018 Suleiman Minhas, Bart De Strooper lab, KU Leuven wrote:
We have used this antibody for IHC staining of 4% PFA perfused mouse brain tissue (vibratome sections). The first batch of the antibody worked okay, but the second and third batch didn’t give good results.
On December 18, 2018 Ebru Ercan-Herbst, BioMed X Innovation Center, Heidelberg, Germany wrote:
This antibody was included in a study testing 49 commercial available Tau antibodies including both pan-Tau antibodies and antibodies specifically recognizing Tau with post-translational modifications (PTM).
The antibodies were tested by peptide array to assess PTM specificity and by immuno-blotting of mouse brain lysates obtained from hTg-Tau (expressing all six human isoforms of Tau) and Tau knock out mice to test Tau specificity. A subset of 35 antibodies was subsequently tested by immunofluorescence staining of human iPSC derived neurons (see reference below for further details)
WB: 1/1000, Very good – strong signal for tau, no non-specific signal
The study was published in Ercan et al. Molecular Neurodegeneration (2017) 12:87 “A validated antibody panel for the characterization of tau post-translational modifications” and demonstrates that commercially available antibodies show a significant lack of specificity. In particular, PTM-specific antibodies very often recognize non-modified version of Tau.
(https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-017-0229-1)